Exhibit 99.1

                                                 Contacts:   LEIV LEA
                                                             Pharmacyclics, Inc.
                                                             (408) 774-0330
                                                             IAN R. MCCONNELL
                                                             WeissCom Partners
                                                             (415) 362-5018

          PHARMACYCLICS ANNOUNCES COMPLETION OF COMMON STOCK OFFERING

SUNNYVALE, CA, APRIL 7, 2004 -- Pharmacyclics, Inc. (Nasdaq: PCYC) today
announced the closing of a previously announced underwritten public offering of
3,200,000 shares of its common stock, which includes shares issued pursuant to
the exercise of the underwriter's over-allotment option. The public offering
price of $13.00 per share results in net proceeds to Pharmacyclics of
approximately $39.6 million.  All of the shares to be sold in the offering are
newly issued shares of common stock of Pharmacyclics.

Pacific Growth Equities, LLC acted as the sole book-running manager and
underwriter of this offering. A copy of the prospectus and accompanying
prospectus supplement relating to the offering can be obtained from Pacific
Growth Equities, LLC at One Bush Street, San Francisco, CA 94104.

This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
jurisdiction.

ABOUT PHARMACYCLICS

Pharmacyclics is a pharmaceutical company developing products to improve upon
current therapeutic approaches to cancer and atherosclerosis. The company's
products are rationally designed, ring-shaped small molecules called texaphyrins
that selectively target and disrupt the bioenergetic processes of diseased
cells, such as cancer and atherosclerotic plaque.


                                     # # #